Clinical Trials
199
Active:9
Completed:91
Trial Phases
5 Phases
Phase 1:8
Phase 2:43
Phase 3:31
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (132 trials with phase data)• Click on a phase to view related trials
Not Applicable
45 (34.1%)Phase 2
43 (32.6%)Phase 3
31 (23.5%)Phase 1
8 (6.1%)Phase 4
5 (3.8%)Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
Not yet recruiting
- Conditions
- HIV SeropositivityHIV Drug ResistanceHIV Infections
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 30060
- Registration Number
- NCT07146529
Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers
Not Applicable
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Biological: CD40.Pan.CoV Low dose(0.25mg)Biological: CD40.Pan.CoV Low dose (0,25mg) adjuvanted with Hiltonol®Biological: CD40.Pan.CoV High dose (1mg)Biological: CD40.Pan.CoV High dose (1mg) adjuvanted with Hiltonol®
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 48
- Registration Number
- NCT07113106
- Locations
- 🇫🇷
Centre de Recherche Clinique CHU de Caen Normandie, Caen, France
🇫🇷CIC 1405 CHU Clermont Ferrand, Clermont-Ferrand, France
🇫🇷Hôpital Henri Mondor, Créteil, France
Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy
Not Applicable
Not yet recruiting
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: ACCESS+ strategy Epclusa 400/100 Oral TabletDrug: Standard Strategy Vosevi 400/100/100 Oral TabletDrug: ACCESS+ Strategy Vosevi 400/100/100 Oral TabletDrug: Standard Strategy Epclusa 400/100 Oral Tablet
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 576
- Registration Number
- NCT07098481
Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption
Not Applicable
Not yet recruiting
- Conditions
- HIV-1-infection
- Interventions
- Other: Placebo of sirolimus 2 MGOther: Placebo of baricitinib 2 MG
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 191
- Registration Number
- NCT07081763
"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"
Not Applicable
Not yet recruiting
- Conditions
- HBV InfectionPregnancy
- Interventions
- Diagnostic Test: HBsAg RDT WomenDrug: Treatment by TDFDrug: Treatment by TDF if HBcrAg RDT positiveOther: Social sciences componentDiagnostic Test: HBsAg RDT Infants
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 3200
- Registration Number
- NCT07054359
- Prev
- 1
- 2
- 3
- 4
- 5
- 41
- Next
News
No news found